Abstract: A multidose transdermal drug delivery system comprises a laminate composite with a plurality of compartments. Each compartment is a reservoir for a unit dose of a drug active to be transdermally administered. The assembly is adhesively secured to the skin of a patient. Individual seals are provided for resealably enclosing the drug active in each of the reservoirs. The individual enclosing seals are removable to release the unit dose into contact with the skin of the patient and are actuable to control the transdermal absorption of the drug actives. Provisions are also made to automatically indicate the activation of the drug and to prevent an accidental release of medicament.

Abstract: A transdermal therapeutic system (TTS) comprising an active substance which is sensitive to hydrolysis, and having a layer-like structure comprising a backing layer impermeable to moisture and active substance, a matrix comprising the active substance, and optionally a protective layer covering the matrix is characterized in that the matrix contains a water-binding component.

Abstract: A transdermal drug delivery system comprising(i) an occlusive, impermeable polymeric backing layer;(ii) a drug depot on one side thereof;(iii) a removable, occlusive covering layer over said drug depot; and(iv) an adhesive means by which said delivery system, absent said removable covering layer may be affixed to an intended patient;said drug depot containing a drug formulation comprising a transdermally administrable pharmaceutically acceptable pharmaceutically active agent or a precursor thereof, water and lower alkanol; said active agent or precursor thereof being present in a pharmaceutically effective amount; said lower alkanol and said water being present in a volume:volume ratio of from 30:70 up to less than 95:5 such that said lower alkanol, water and drug are delivered to a patient's skin, which patient has applied said system absent said removable covering layer to said patient's skin, in amounts that said drug is delivered in a transdermally administrable efficacious amount, said water has an activ

Abstract: A composition for use in a three layer transdermal delivery system is disclosed, the composition comprising an adhesive matrix having sufficient strength to maintain an association on the skin for at least 3 days. The adhesive matrix contains the flux enhancer linoleic acid, an anti-oxidant and an effective dose of one or more steroid hormones with female sex related activity.

Abstract: Varying the daily dose of either or both of the estrogen and the progestogen administered for hormone replacement therapy (HRT) is readily and inexpensively accomplished, without the necessity of the physician prescribing a new product each time the daily dose of the estrogen or progestogen is changed, by administering preferably transdermally the estrogen and the progestogen contained in separate extrudable pharmaceutical compositions from a dispenser which contains means, preferably adjustable only by the attending physician or dispensing pharmacist, for varying the volume of either or both of the respective compositions which is dispensed as a single dose from the dispenser in response to a defined digital dispensing manipulation of the dispenser thereby facilitating optimal compliance to a combination of HRT with individually adjusted dosages of the estrogen and progestogen.

Abstract: A method for increasing the rate and extent of fiber digestion in a ruminant after ingestion by the ruminant is described. The method includes forming an aqueous mixture including carbohydrase enzymes active on structural carbohydrates of a forage and applying the aqueous mixture to the forage prior to ingestion by the ruminant at an application ratio grater than about 20 milliliters of the aqueous mixture per pound of forage dry matter.

Abstract: A delivery system is disclosed for delivering a fluid-sensitive active agent such as a somatotropin, or an analogue or derivative thereof, to an animal such as a bovine. The delivery system comprises a first wall section, a second wall section and a locking coupling therebetween. The coupled wall sections define a compartment, enclosing an active agent and an expandable driving member. Various embodiments of the locking coupling are disclosed.

Abstract: The invention relates to stable, pharmaceutically usable chewing gum formulations which contain acetylsalicylic acid (ASA) as the active compound, and to a process for their preparation.

Abstract: The invention provides a controlled release composition comprising a compressed core containing a drug having two parallel planar surfaces (i.e. the top and bottom), and a seal coating surrounding the core except on said planar surfaces (i.e. on all lateral surfaces). The seal coating comprises a film coating of an impermeable material.

Abstract: An analgesic agent delivery system and method of treating postoperative pain comprising an analgesic agent such as morphine and an extended-release drug delivery device. The device may be placed in the vicinity of a wound and then provide an extended-release of the analgesic agent over a period of time, thereby controlling the pain emanating from the wound.

Abstract: The present invention comprises a composition comprising a matrix adapted to be placed in drug-and permeation-enhancing mixture-transmitting relation to a selected skin or other body site. The matrix contains sufficient amounts of drug, permeation enhancer(s) and poly-N-vinylamide to continuously administer to the site, the drug, in a therapeutically effective amount, and the permeation-enhancing mixture, in an amount effective to enhance the permeation of the skin to the drug. The device shows increased transdermal flux, as compared to the transdermal flux of the drug from a device containing no poly-N-vinyl amide. Incorporating poly-N-vinyl amide into the transdermal system also improves the adhesion and stability of the system.

Abstract: An apparatus, product formulation, and method for improved dermal permeation of pharmaceuticals wherein the apparatus includes a thin drug formulation reservoir and a heat-generating chamber separated by a first non-permeable wall, wherein the reservoir and chamber are formed in or supported by a housing. The drug formulation reservoir houses or is capable of housing a predetermined amount of a formulation containing pharmaceutically-active agent(s). The heat-generating/temperature-regulating chamber includes a medium for generating controlled heat, preferably a chemical composition made of carbon, iron, water and/or salt which is activated upon contact with air (oxygen).

Abstract: A novel system for percutaneously delivering at least two active principles, consisting of at least two juxtaposed devices. The system includes (i) a first device containing a mixture of all the active principles in which at least one first active principle (A) is present in an amount enabling the effective therapeutic dose to be delivered, and at least one second active principle (B) is present in an amount smaller than the amount needed to deliver the effective therapeutic dose; and (ii) one or more additional devices each containing a single active principle (B) selected from those in the first device and provided in an amount smaller than the amount needed to deliver the effective therapeutic dose, said additional device(s) being designed to top up the amount of each of the active principles (B) in the system until the effective therapeutic dose is achieved.

Abstract: An iontophoretic drug delivery system including a plurality of patches, at least one reusable controller and a unit for storing and dispensing the patches. The patches may be secured in a compartment formed in the unit and the controller may be stored in another compartment formed in the unit. In this way, the reusable controller and a new patch can be removed from the unit and fastened to one another for activation and attachment to the skin of a patient.

Abstract: The present invention is directed to a pharmaceutical compositions improving percutaneous absorbability by absorption assistants, which remarkably increase permeation and dissolution of piroxicam, and penetration enhancers. A further surprising feature of the present invention resides in the fact that absorption assistant which assists penetration enhancer is able to include the active substance excessively in adhesive matrix as solvent of the active substance.

Abstract: Alginate fibres comprising at least one medicament incorporated into the structure thereof, the medicament being present at a level of at least 10% by weight, based on the weight of the alginate fibre with no incorporated medicament.

Abstract: The dressing for heavily exuding wounds comprises a hydrophilic foam having an absorptive capacity of at least 10 times its own weight, such as a hydrophilic polyether polyurethane foam material derived from a foamable composition comprising a polyol component containing ethylene oxide groupings. For use on bleeding wounds and/or to improve the absorptive capacity of the foam itself, the foam may be impregnated with alginate, which acts both as a haemostat and as an absorption improver. The dressing may include a backing layer which provides a barrier to microorganisms.

Abstract: Methods and devices for preventing and/or treating an adverse reaction of the skin to the presence of a skin-sensitizing and/or skin-irritating agent by administering an effective amount of a loop diuretic alone or in combination with at least one mast cell degranulator or at least one glucocorticosteroid.

Abstract: There is disclosed a composition and method for reducing or alleviating the discomforting symptoms associate with menstruation, particularly menstrual pain. The composition is administered by topical or local administration to the uterus or vaginal tissues of a women in need thereof, and contains an omega fatty acid in combination with a cyclo-oxygenase inhibitor. Preferred omega fatty acids include docosahexaenoic acid and eicosapentaenoic acid, and preferred cyclo-oxygenase inhibitors include, ibuprophen, acetylsalicylic acid and salicylic acid. The composition may further include pharmaceutically acceptable carriers or diluents, and may be locally applied via intracervical or intrauterine application, or may be topically applied to the skin of the lower abdomen.

Abstract: The invention concerns a transdermal therapeutic system comprising the active substance 17-.beta.-estradiol and optionally further active substances, with a laminated structure comprising a backing layer which is substantially impermeable to moisture and impermeable to active substance, one or more matrix layers and, where non-adhesive matrix layers are present, an adhesive layer, characterized in that the concentration of the dissolved estradiol in all matrix layers and, where an adhesive layer is present, in the adhesive layer lies between its saturation concentration in dry condition und its saturation concentration in moist condition, whereby the term "dry condition" is understood to mean that the base material is in equilibrium with a gas phase with less than 10% relative humidity and the term "moist condition" is understood to mean that the base material is in equilibrium with a gas phase with more than 90% relative humidity.